Skip to main content

Complications of Peptic Ulcer Disease!

 COMPLICATIONS OF PEPTIC ULCER DISEASE

  1. Bleeding peptic ulcer
  2. Pyloric stenosis
  3. Zollinger-Ellison Disease
  4. Stress Ulcers


Bleeding peptic ulcer:

  • Peptic ulcer is the most common cause of non-variceal upper gastro-intestinal bleeding.
  • Most patients with bleeding peptic ulcer are clinically stable and stop bleeding without any intervention, whereas other outcomes include re-bleeding and mortality.
  • Endoscopy allows identification of the severity of disease.
  • Endoscopic hemostatic therapy which is successful in reducing mortality.
  • A number of pharmacological agents have been used for endoscopic injection therapy such as 1:10000 adrenaline (epinephrine), human thrombin and fibrin glue.
  • Mechanical endoscopic treatment options include Thermocoagulation using a heater probe or endoscopic clipping.
  • Combination therapies are superior to monotherapy and a combination of adrenaline 1:10000 with either thermal or mechanical treatment is recommended (SIGN,2008).



Pyloric Stenosis:

Malignancy is the most common cause of gastric outlet obstruction.
Peptic ulcer disease is the underlying cause in about 10% of cases.
Conventional treatment with acid-suppressive therapy may also help.
If medical therapy fails to relieve the obstruction, Endoscopic balloon dilation or surgery may be required.


Zollinger-Ellison Syndrome:

  • This is a rare syndrome that consists of a triad of non-beta cell tumors of the pancreas that contain and release gastrin, gastric acid hypersecretion and severe ulcer disease.
  • Extra-pancreatic gastrinomas are also common and may be frequently found in the duodenal wall.
  • A proportion of these patients have tumors of the pituitary gland and parathyroid gland.
  • Patients with idiopathic peptic ulcer disease should be investigated for Zollimger-Ellison Syndrome.
  • Medical management includes; greater than standard doses of Proton Pump Inhibitors. The somatostatin analogue OCTREOTIDE is also effective but has no clear advantage over PPIs.


Stress Ulcers:

  • Sever physiological stress such as Head Injury, Spinal cord injury, Burns, Multiple traumas or Sepsis may induce superficial mucosa erosions or gastroduodenal ulcerations. These may lead to hemorrhage or perforation.
  • Diminished blood flow to the gastric mucosa, decreased cell renewal, diminished prostaglandin production and hypertension are involved in causing stress ulceration.
  • Management involves: Intravenous acid-suppression therapy, Histamine H-receptor antagonists, PPIs and Nasogastric tube administration of SUCRALFATE (4-6g daily in divided doses) have been used to prevent stress ulceration in the intensive care unit until patient tolerates enteral feeding.
Most commonly used regimens are: IV Ranitidine 50mg every 8hr reducing to 25mg in severe renal impairment.
  • Patients at Mechanical ventilation and the presence of coagulopathies are at higher risks of stress-related mucosal bleeding and may require prophylactic treatment.


Labels:

Comments

Post a Comment

Popular posts from this blog

Procedure of IV selection!

 IV DRUG THERAPY- SELECTION OF EQUIPMENTS AND INSERTION OF CATHETER Equipment: Canula selection: Select cannula based on purpose and duration of use and age of patient. Consider risk of infection and extravasation. Cannula made from polyurethanes are associated with decreased risk of phlebitis. Steel needles have higher risk of extravasation and should be avoided where tissue necrosis is likely if extravasation occurs.       2. Skin Prep: Antiseptic solution, use an aqueous based alternative if there is a known allergy to alcohol.       3. Other Equipment: Intravenous solution as ordered, torniquet, giving set, IV stand/pole, infusion pump, transparent occlusive dressing, tape or similar to secure cannula, gloves, paper bag.       4. Additional Equipment which may be required: Syring (5mL), sterile sodium chloride 0.9%, local anesthetics (in children), 3-way tap or triflow, short extension tube. Selection Of the Catheter Site: Generally ...
Post a Comment
Read more

Anatomy and the Complications Associated with Liver Diseases!

  LIVER AND THE COMPLICATIONS ASSOCIATED WITH THE PROGRESSION OF DISEASE! Liver: The liver weighs up to 1.5kg in adults and is the 2nd largest organ in the body. Hepatocytes are the functioning unit of liver. Impairment of liver may lead to: Acute liver diseases Chronic liver diseases Liver cirrhosis Acute Liver Disease (ALD): ALD is a self-limiting episode of hepatocyte damage which in most cases spontaneously without clinical sequelae, but acute liver failure (ALF) may develop. This is a rare condition in which there is a rapid deterioration in liver function with associated encephalopathy and coagulopathy. ALF carries significant morbidity and mortality and may require emergency liver transplant. Chronic Liver Disease (CLD): CLD occurs when the longstanding cell damage causes permanent structural changes within the liver, with the loss of normal liver structure and functions. In many cases, this may lead to cirrhosis where fibrosis sears divide the liver cells into areas of rege...
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-5...
Post a Comment
Read more